{"_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4O601qoKDA","lastupdate":"2022-11-22T00:00:00.000Z","update_date":"2022-11-22T00:00:00.000Z","lastModified":"Jun 7, 2022","active":1,"confidence_score":90,"confidence_score_reason":"markets, not claimed","urlname":"migvax","minimal_profile":null,"status":"","fullstatus":"","acquired":0,"hide_reason":null,"hide_reason_data":null,"hide_reasons":[{"id":"8257rxn4P8EFQOmS5hAAauHyYMhhxrA5u6yWX4XUShpybX3AMNo3Y9","reason":"Pending approval - External entity"},{"id":"aOIaOiiqfpA8UMw6VCTh8ueRmkG3lzDy1NGqEOaJbe11OrCzMTCCd6","reason":"The company is a service provider"},{"id":"ddgjKuc3GgH8E5UehSVJviRl471BCajL1plO8HtGoOojy2NivYqQ7x","reason":"Owner asked to delete"},{"id":"EjOKM211H1ira9J63oaGPuUxvr7Oba55TZo3NWsFO5uhbNu7o4x4zD","reason":"The company is not Israeli"},{"id":"J7fQJtnT3GdWWSE3MD8rzaW65LJ4jEIKxSZnneQiReONdZjG3zIqWe","reason":"Owner asked to hide in the meantime"},{"id":"NxlAC3ReFb5ksiYNLp2FnUyluoJzwRCYfcF7xpTZaPM53SdWQ5kv0B","reason":"Pending approval"},{"id":"RhC1tlwXzioK0MfzBII3H2wepEfQOfKVktmdwqeqTJjGi3ZaBWUqZo","reason":"The company is not innovative"},{"id":"S0Ed46vNI6vZYVxLedANWGjas23K6hY0QdsCtiGYL7lshqIEdLV3sA","reason":"The company ceased operations in Israel"},{"id":"VTANq7bEvlsEcPjp0ghelXfShaCosgndONGjgU730aAOxXtaDIF5j3","reason":"This is a product of an existing company"}],"type":"Startup","logokey":"$tmjQ7WJeCcpkiRfvlGTxQrN1jQgf3YxL43lAyGBo4HbOfYGzkHvBXV","name":"MigVax","oneliner":"Vaccine for Viruses in Humans","registrar":"516178084","website":"https://www.migvax.com/","careerspage":"https://www.migvax.com/careers","founded_month":3,"founded_year":2020,"formernames":[],"sociallinks":{"twitter":"","youtube":"","facebook":"","linkedin":"https://www.linkedin.com/company/82100394","instagram":""},"social":["https://www.linkedin.com/company/82100394"],"flattenedsociallinks":"https://www.linkedin.com/company/82100394","apps":{"appstore":"","googleplay":""},"is_claimed_by_owner":null,"employees":"1-10","employees_exact":9,"patent":0,"raised":21300000,"stage":"A","public_stage":"A","primary_sector_key":"agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","primary_sector":"Health Tech & Life Sciences","alternativenames":["Mig Vax","The MIGAL Galilee Research Institute","Migal","Mig.Vax","Mig-Vax"],"about":"MigVax was established as a special purpose vehicle by Migal, which granted MigVax an exclusive, worldwide license to make, use, and practice the vaccine technology for the development, manufacture, and commercialization of vaccines for viruses in humans, starting with COVID-19.\n\nThe COVID-19 vaccine project was initiated upon the interdisciplinary research team’s successful development of a vaccine against infectious bronchitis virus (IBV), an avian (poultry) coronavirus with high similarity to today’s human COVID-19 that uses the same infection mechanism. Given the similarity, and following the required genetic adjustments, the same vaccination concepts should apply.\n\nMigVax’s sub-unit vaccine approach utilizes a chimeric protein that presents the viral proteins to the immune system via the oropharynx. This method, based on the IBV vaccine, generates three types of immunological response: mucosal immunity (IgA), blood-based immunity (IgG), and cell-mediated immunity.","climatetech_description":null,"is_climatetech_relevant":null,"phone":"+97246953511","country":null,"address":{"israeli":[{"id":"1417820c-1a4b-4d45-adf1-857fcb0353ca","city":"Qiryat Shemona","type":null,"address":"Tarshish Street 5, Kiryat Shmona, Israel","placeid":null,"notactive":0,"openeddate":null,"registrarid":null,"firstrdcenter":0,"registrarname":null}],"officesabroad":null},"headquarter_address":null,"district":"North District","news":[{"id":"19adfcd3-601f-441a-9c4d-cac28896f285","date":"Jun 7, 2022","link":"https://www.prweb.com/releases/catalent_and_migvax_sign_agreement_to_develop_an_orally_disintegrating_freeze_dried_tablet_vaccine_against_covid_19/prweb18719488.htm","source":"www.prweb.com","visible":1,"analysis":{"tags":["vaccine","technology"],"company":"Catalent","layoffs":null,"summary":"Catalent and MigVax have signed a development agreement to utilize Catalents Zydis Bio orally disintegrating tablet (ODT) technology for delivering the MigVax-101 vaccine. The partnership aims to simplify the transportation, storage, and administration of the oral COVID-19 vaccine, making it easier and cost-effective for mass-vaccination programs. Catalent will conduct a feasibility study to formulate MigVax-101 into a Zydis Bio ODT dose form. The Zydis technology offers advantages such as improved patient compliance and convenience. The collaboration between Catalent and MigVax is a major step forward in global distribution and addressing the challenges of cold chain storage and transport. Catalents Zydis facility in Swindon, U.K., will carry out the work.","partners":["MigVax"],"customers":null,"investors":null,"confidence":9,"key_topics":["vaccine","technology","partnership","oral delivery","COVID-19"],"date_of_event":"2022-06-07","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"bRfSDgCaPbbcdX3YrxZ8FfDRdibjnZkW6VlBQisCmKmT1CqJbWvOxB","news_summary":"Catalent and MigVax Sign Agreement to Develop an Orally Disintegrating Freeze-Dried Tablet Vaccine Against COVID-19","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"N3sNmK5hp5yYhz1RLZO5AE0GgQbHNVmxKrPObQAyRowcWLIMeyDTMt","date":"May 31, 2022","link":"https://www.einnews.com/pr_news/574688935/migvax-appoints-ran-amir-as-its-new-ceo","source":"www.einnews.com","visible":1,"analysis":{"tags":["COVID-19","vaccine","CEO appointment","scaling up","clinical trials"],"company":"MigVax Ltd.","layoffs":null,"summary":"MigVax Ltd. has appointed Ran Amir as its new CEO as the company prepares to scale up its business and advance its oral subunit vaccine against COVID-19. The company has achieved proof-of-concept and received a prestigious grant for its groundbreaking vaccine. Ran Amir, with experience in scaling up technology-focused startups, is expected to accelerate MigVaxs momentum. The companys next-generation sub-unit oral vaccine aims to meet market needs for affordable and easier-to-administer booster solutions. MigVax is currently seeking financing for its Phase 1 & 2 clinical trials. The companys vaccine has demonstrated positive results in preclinical tests. MigVax is an affiliate of The Migal Galilee Research Institute and received investment from OurCrowd.","partners":null,"customers":null,"investors":"OurCrowd","confidence":9,"key_topics":["COVID-19 vaccine","CEO appointment","scaling up","clinical trials","investment"],"date_of_event":"May 31, 2022","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Management Changes","Expand"],"acquisition_amount":null,"structuredIssuesShow":"#Management Changes  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"d6qAAQS455Ab1zWQREQgh0omSJmjtsEY5j6SkJBl4jXRDLPpr1KaX4","news_summary":"MigVax Appoints Ran Amir As Its New CEO","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"cef55a83-1136-46df-ad0d-38559469d02f","date":"Nov 5, 2021","link":"https://www.jpost.com/health-and-wellness/coronavirus/israels-migvax-oral-vaccine-scores-34-m-to-fast-track-development-684020","source":"www.jpost.com","visible":1,"analysis":{"tags":"COVID-19, vaccine development","company":"MigVax","layoffs":null,"summary":"MigVax, an affiliate of MIGAL Galilee Research Institute, has received a $4.3 million grant from the Coalition of Epidemic Preparedness Innovations (CEPI) to develop its COVID-19 oral subunit vaccine tablet. The grant is part of a $200 million program to advance the development of vaccines that provide broad protection against COVID-19 variants or future coronaviruses. MigVax plans to use the grant to bring its vaccine to market faster and explore its potential use against other coronaviruses. The vaccine, called MigVax-101, is an oral subunit vaccine that presents the coronavirus antigen to the immune system without introducing pathogen particles. The grant recipients are required to commit to achieving equitable access to the vaccine outputs. CEPI is a partnership of public, private, philanthropic, and civil organizations focused on developing vaccines against future pandemics.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["MigVax","COVID-19","vaccine","grant","CEPI"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"lcNseRQavtU21MQgeV8cIRjqyjMviJRzxeeKyyfIuUT5IAbmwq2r2x","news_summary":"https://www.jpost.com/health-and-wellness/coronavirus/israels-migvax-oral-vaccine-scores-34-m-to-fast-track-development-684020","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"7ba1aab2-6ece-4528-bde0-0b7fc784b7cc","date":"Jun 10, 2021","link":"https://www.businesswire.com/news/home/20210610005425/en/MigVax%E2%80%99s-Subunit-Oral-COVID-19-Vaccine-Preclinical-Trial-Demonstrates-Effectivity-as-a-Booster","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"t2L8zV95cvnRx86L64fRvIUAYYhvfTXze12XC3tS5tOPEP4RBevMau","news_summary":"MigVax's Subunit Oral COVID-19 Vaccine Preclinical Trial Demonstrates Effectivity as a Booster","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"f8964642-3eca-4023-bf6b-2adbda6f1326","date":"Dec 7, 2020","link":"https://www.timesofisrael.com/spotlight/after-coronavirus-vaccine-success-is-israels-migvax-still-needed/","source":"www.timesofisrael.com","visible":1,"analysis":{"tags":"COVID-19, vaccines, treatments, pandemic","company":"MigVax","layoffs":null,"summary":"Israeli medical entrepreneurs emphasize the need for additional vaccine and treatment options to end the COVID-19 pandemic. MigVax, an Israeli company, is developing an oral vaccine for COVID-19 that could be available next year. The vaccine offers the advantage of being simple to distribute and use. SaNOtize, a Vancouver-based startup, has developed a nasal spray that kills COVID-19 and other infections. Clinical trials are underway to confirm the safety of the spray. The spray could be on the market as a preventative measure in mid-2021. The pandemic has also highlighted the need for breakthroughs and new methods to prevent or treat other viruses and improve the healthcare system.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["COVID-19 vaccines","Preventative measures","Treatment options","Logistical challenges","Opportunities for healthcare system"],"date_of_event":"2020-12-10","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers","Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Customers  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"Scz2dyMq3iAcs6npdo4qsKcMoIjMkiSx7rCsNXqddLquJr5z4OakT8","news_summary":"After coronavirus vaccine success, is Israel's MigVax still needed? - Sponsored Content  The Times of Israel","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"f1e115b5-de66-4b4c-8e86-55c3367b0080","date":"Jun 9, 2020","link":"https://en.globes.co.il/en/article-ex-teva-cfo-eyal-desheh-joins-israeli-covid-19-vaccine-co-1001331715","source":"en.globes.co.il","visible":1,"analysis":{"tags":"vaccine development","company":"MigVax","layoffs":null,"summary":"Israeli company MigVax has appointed Eyal Desheh as chairman of its board of directors. MigVax is developing an oral vaccine against Covid-19 based on research from the Migal Galilee Research Institute. Deshehs experience in the pharmaceutical industry is expected to assist MigVax in their vaccine development efforts. The company aims to turn the promising technology into an effective vaccine and build an advanced platform for further vaccine development.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["MigVax","vaccine development","Eyal Desheh","Migal Galilee Research Institute","Covid-19"],"date_of_event":"June 9, 2020","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners","Expand"],"acquisition_amount":null,"structuredIssuesShow":"#Partners  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"EPlSms6wSxblmF4t3rw2oEChW2IBC84k6YT7L88qUom0HlAKasRBMJ","news_summary":"Ex-Teva CFO Eyal Desheh joins Israeli Covid-19 vaccine co","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"76d93ef8-504d-4b09-a2ba-06f365004c66","date":"Apr 22, 2020","link":"https://en.globes.co.il/en/article-israeli-covid-19-vaccine-developer-migvax-raises-12m-1001326111","source":"en.globes.co.il","visible":1,"analysis":{"tags":"vaccine development","company":"MigVax Corp.","layoffs":null,"summary":"Israeli Covid-19 vaccine developer MigVax Corp., an affiliate of the Migal Galilee Research Institute, has raised $12 million in funding led by OurCrowd. MigVax aims to develop a new oral subunit human vaccine against Covid-19 using methods learned from a previous vaccine developed by the institute. The vaccine has shown high safety and efficiency in animal models, and the company plans to have the material ready for clinical trials within a few months.","partners":null,"customers":null,"investors":"OurCrowd","confidence":9,"key_topics":["Covid-19 vaccine","MigVax Corp.","OurCrowd","Migal Galilee Research Institute","vaccine development"],"date_of_event":"April 22, 2020","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$12 million","structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"cFB2YzN5H1yGmvOWCNso6aEmOBW3Bg64Su6nFPKntAcE5bhIEQBz30","news_summary":"Israeli Covid-19 vaccine developer MigVax raises $12m","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"c0f30f8a-2989-4fec-9096-5565e1da504e","date":"Apr 22, 2020","link":"https://techcrunch.com/2020/04/21/migvax-raises-12m-for-its-covid-19-vaccine-efforts/","source":"techcrunch.com","visible":1,"analysis":{"tags":"COVID-19 vaccine","company":"MigVax","layoffs":null,"summary":"Israeli startup MigVax receives $12 million investment from OurCrowd to accelerate the development of an oral COVID-19 vaccine. MigVaxs approach, which uses bacterial fermentation to produce the vaccine, offers advantages in manufacturing and cost. The company aims to have the material ready for clinical trials within a few months. OurCrowd CEO Jon Medved expresses gratitude for the opportunity to support the important effort of developing a COVID-19 vaccine. The funding reflects the growing interest and investment in startups working on COVID-19 vaccines.","partners":"OurCrowd","customers":null,"investors":"OurCrowd","confidence":8,"key_topics":["COVID-19 vaccine","MigVax","OurCrowd","vaccine development","funding"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$12 million","structured_issues":["Investment","Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Investment  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"kQ8MaJVWQjwMW9AvOR7BQqM2BUmnWwPznkRlUId1CxRtl5142zYMLI","news_summary":"MigVax raises $12M for its COVID-19 vaccine efforts","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"9e00e7d9-462d-49a1-9bc3-7d0ff8665c4f","date":"Apr 22, 2020","link":"https://blog.ourcrowd.com/migvax/","source":"blog.ourcrowd.com","visible":1,"analysis":{"tags":"investment","company":"OurCrowd","layoffs":null,"summary":"OurCrowd, the worlds largest crowdfunding venture investment platform, is leading a $12 million investment in MigVax Corp., an Israeli company developing a novel COVID-19 vaccine. MigVax is an affiliate of The Migal Galilee Research Institute and is using methods learned from a previous vaccine to develop a new oral subunit human vaccine against COVID-19. The investment will accelerate the path to clinical trials and bring the vaccine to market. OurCrowd CEO Jon Medved expressed gratitude for the opportunity to support this important effort. The vaccine has shown high safety and efficiency in animal models, and the approach taken by MigVax is believed to be safer with a higher likelihood of achieving a meaningful immune response.","partners":null,"customers":null,"investors":"OurCrowd","confidence":9,"key_topics":["COVID-19 vaccine","investment","clinical trials","MigVax Corp.","Migal Galilee Research Institute"],"date_of_event":"April 22, 2020","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$12 million","structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"VTWzU0cP3bBNR9nRtHnM7f8rpP5VzqVxlM6Y2e2bjwAmTmAxhONmyz","news_summary":"PRESS RELEASE: OurCrowd Leads $12M Investment in Israeli Covid-19 Vaccine Company MigVax - OurCrowd Blog","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"80e4ad76-c6fc-46b8-95d0-446076444c3f","date":"Apr 13, 2020","link":"https://www.jpost.com/HEALTH-SCIENCE/Israeli-scientists-In-three-weeks-we-will-have-coronavirus-vaccine-619101","source":"www.jpost.com","visible":1,"analysis":{"tags":"vaccine development","company":"MIGAL","layoffs":null,"summary":"Israeli scientists at MIGAL are close to developing the first vaccine against the novel coronavirus. The vaccine could be ready within a few weeks and available in 90 days. MIGAL has been working on a vaccine for infectious bronchitis virus (IBV), and they found that the poultry coronavirus has high genetic similarity to the human one. They are adjusting their system to the new sequence and hope to have the vaccine in a few weeks. MIGAL is in discussions with potential partners to accelerate the in-human trials phase and expedite final-product development and regulatory activities.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["Vaccine","Coronavirus","MIGAL","Development","Partnerships"],"date_of_event":"February 2020","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Investment","Partners","Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Investment  #Partners  #Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"CYVAnEQn0QluhFaVO9N54GCrDdwM5nqzyBlj7KgEJUWO83PEF0xYz2","news_summary":"https://www.jpost.com/HEALTH-SCIENCE/Israeli-scientists-In-three-weeks-we-will-have-coronavirus-vaccine-619101","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"163d7eb4-f68a-4822-9e2e-f8ed603d3a4c","date":"Mar 5, 2020","link":"https://scrip.pharmaintelligence.informa.com/SC141784/Israeli-RD-Team-Claim-To-Be-Near-COVID19-Vaccine","source":"scrip.pharmaintelligence.informa.com","visible":1,"analysis":{"tags":"COVID-19 vaccine","company":"MIGAL","layoffs":null,"summary":"Israeli research team MIGAL has discovered a potential COVID-19 vaccine candidate as a by-product of an avian vaccine they were developing. They hope to start producing and testing the vaccine by May.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["COVID-19 vaccine","avian vaccine","producing","testing","May"],"date_of_event":"2020-05-01","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Investment","Expand"],"acquisition_amount":null,"structuredIssuesShow":"#Investment  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"4Zz8ZFMXA79BL2iLRIoDcsE8u1K2fIKstDxoKffPEKzD9rlBkQQ29b","news_summary":"Israeli R&D Team Claim To Be Near COVID-19 Vaccine","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"04092ba4-93cd-417c-8d80-75b962625c8b","date":"Mar 3, 2020","link":"https://nocamels.com/2020/03/israeli-scientists-avian-vaccine-adapt-coronavirus","source":"nocamels.com","visible":1,"analysis":{"tags":"Vaccine Development","company":"Migal Research Institute","layoffs":"Not mentioned","summary":"Scientists at the Migal Research Institute in Israel have developed a vaccine for a deadly virus affecting poultry that could be adapted for human use against the novel coronavirus. The vaccine has been proven effective in pre-clinical veterinary trials. The scientists identified a possible COVID-19 vaccine candidate as a by-product of the avian vaccine and have made the required genetic adjustments to adapt the vaccine to COVID-19. The institute aims to produce the vaccine over the next two months and achieve safety approval in 90 days.","partners":"Galilee Development Company Ltd","customers":"Not mentioned","investors":"Not mentioned","confidence":8,"key_topics":["Coronavirus","Vaccine","Research","Investment","Partnerships"],"date_of_event":"March 2020","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Investment","Partners"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"LP3aANj1Hut16FWCKccEcOOoIn0c5rYzCBG5yH5MtD4yzpR0OhXqnD","news_summary":"Israeli Scientists Work To Test Adapted New Avian Virus Vaccine Against Human Coronavirus","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"}],"newsNumber":12,"techcommunityinvolvement":null,"mediagallery":[{"id":"23c3e0b5-bf66-44ae-ace8-23fd6d28d5b5","timestamp":"2020-04-22 08:45:30.000000","resources_type":2,"resources_title":"","resources_file_name":"zjPKCSa24a8","alt":"","imageurl":"https://img.youtube.com/vi/zjPKCSa24a8/0.jpg","url":"http://youtu.be/zjPKCSa24a8"}],"tags":["immunology","pharmaceuticals","drug-development","oral-drugs","vaccines"],"classificationIDs":["agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Jvz7ewLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA"],"technologysuccessstory":null,"usecases":[],"businessmodels":["B2B"],"productstage":"R&D","products":[],"geomarkets":[],"targetmarkets":[],"marketcapital":null,"marketcapitaldate":null,"funding":{"investors":2,"lastfunding":"$500K","totalrounds":4,"fundingstage":"A","totalfunding":"$21.3M","publicinvestors":2,"lastpublicfunding":500000,"totalpublicrounds":4,"totalpublicfunding":21300000},"team":[{"name":"Ran  Amir","email":"ran@migvax.com","phone":"","gender":"Male","userid":"TTn3EizKph1AWjbuiYVfmbbYgKH9szQvMfvY6wfAyOPeR9WHiwmEz0","bounced":true,"claimed":null,"founder":0,"urlname":"ran-amir-1","visible":1,"memberid":"aVwgsm6uTHWEj0YgpISBCGxYpQ0f3RFX4gM2b1jBRpmDh6JY6o1oaU","position":"CEO","last_name":"Amir","claimtoken":"lTgvgPullWpjEQORYgS4oAUPVBWva1McaTw0WmXEEZobIndYCyq8nQ","first_name":"Ran ","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/ran-amir-616a343/","unsubscribed":false,"is_activeuser":0,"additionalemail":"","claimedemaildate":"2022-11-22 13:22:52.000000","initials":"RA","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"David Zigdon","email":"davidz@migal.org.il","phone":"0543001212","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4M6jwZMLDA","bounced":false,"claimed":0,"founder":0,"urlname":"david-zigdon-1","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDg7rTWqgsM","position":"CEO - Migal Galilee Research Institute","last_name":"Zigdon","claimtoken":"7ea5a082fcf669a7342daf16d0acb92326ed326f369986ff95aeb7240695ef16","first_name":"David","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/david-zigdon-8b37483/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2021-11-15 08:07:22.000000","initials":"DZ","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Sigal  Kremer-Tal","email":"sigal@migvax.com","phone":"","gender":"Female","userid":"tXTDDjBHcNNrGjVKjUjfYEdnU3XY1V53K9yvsHuF1iMPxln4UTj2be","bounced":true,"claimed":null,"founder":0,"urlname":"sigal-kremer-tal-1","visible":1,"memberid":"RD0CeA1YmtvYHXnvYgnr3tV6vBUzlxYAjNRsFsDODKfbCyJiG3K2bC","position":"VP Clinical & Regulatory","last_name":"Kremer-Tal","claimtoken":"UKb1K0DqQLMA7QOoM4j0QusVvH1lfbHAWkfCtN2xWfMGdMq1dIN7fw","first_name":"Sigal ","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/sigal-kremer-tal-1297981/","unsubscribed":false,"is_activeuser":0,"additionalemail":"","claimedemaildate":"2022-11-22 13:27:17.000000","initials":"SK","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Ofira  Carmi","email":"ofira@migvax.com","phone":"","gender":"Female","userid":"xdre3jNSEIwjMixBXRbgfObwg7zeiuoHpvRak2u8cFPxSRzvFO6fGA","bounced":false,"claimed":null,"founder":0,"urlname":"ofira-carmi","visible":1,"memberid":"hPQDBqtM5XN2Q97yHj7IswVidPTVXk6VP8UJoBEexaCGvonaVsIjj8","position":"VP R&D","last_name":"Carmi","claimtoken":"sTkp7VE8P0zvYVV1plpHmU9g7k7Gs58G8PS9lANr3C9kKYQ2cyXynq","first_name":"Ofira ","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/ofira-c-81851b31/","unsubscribed":false,"is_activeuser":0,"additionalemail":"","claimedemaildate":"2022-11-22 13:26:00.000000","initials":"OC","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""}],"description_edited":1,"tag_line_edited":1,"sector":"Pharmaceuticals","sectorverify":null,"biverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgMGgoMMJDA","fullname":"Yanina Wainscheinker"},"biverifydate":"2020-07-23T00:00:00.000Z","crunchbaseid":"migvax","lastupdator":"Yanina Wainscheinker","lastupdator_email":"yanina.wainscheinker@sncentral.org","creator":"Yotam Maman","creator_email":"yotamm1988@gmail.com","createdate":"2020-04-22T00:00:00.000Z","biverification":"Yanina Wainscheinker","sectorverification":null,"affiliatedOrganizations":null,"timeline":[{"id":"fkYqgLc12uNEN9fVHcklK4PCNaCTRtzZFUJDRLYRpjXV9ahZEghT03","date":"Aug 2022","amount":"$500K","source":"2022 Survey","eventtype":"FundingRoundEvent","investment":[{"name":"OurCrowd","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/ourcrowd","logokey":"$7IbHrXXd8dSbWrifZtvAYNCvwQvEjxCgGJeOg7DXKENs3TbpV3W9g1","tagline":null,"urlname":"/investor_page/ourcrowd","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgP7H-oQKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"BmNica7hiFMhm4mgszDUKrLAMU5vAj1ZYSz9h38QuE4EjeJGOER1QE","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$7IbHrXXd8dSbWrifZtvAYNCvwQvEjxCgGJeOg7DXKENs3TbpV3W9g1","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":"Follow on "}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Convertible Debt","style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Private Equity Funding","amountnumber":500000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"EZFf0ahwz2jaIyKZJsUsD34tw1b5RIfnFysRKGSP0rTr1DLylYmhEW","date":"Dec 2021","amount":"$500K","source":"2022 Survey","eventtype":"FundingRoundEvent","investment":[],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Convertible Debt","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":500000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgJCIvNm1Cww","date":"Nov 2021","amount":"$4.3M","source":"https://www.jpost.com/health-and-wellness/coronavirus/israels-migvax-oral-vaccine-scores-34-m-to-fast-track-development-684020","eventtype":"GrantEvent","granttype":0,"investment":[{"name":"The Coalition of Epidemic Preparedness Innovations (CEPI)","type":"Other","amount":0,"hidden":false,"country":"Norway","fullurl":"/company_page/the-coalition-of-epidemic-preparedness-innovations-cepi","logokey":"$di6whFrza8jq1EjerFjFw3CTYo7T8wi04nY6zfpko5N5dIQ7JbtC1I","tagline":"Innovation Partnership for Developing Vaccines to Stop Future Epidemics","urlname":"/company_page/the-coalition-of-epidemic-preparedness-innovations-cepi","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgJCo7YapCQw","fundingtype":"Other","leadpartner":null,"investmentid":"8951ee70-0616-4310-8a03-9e9414a4e07c","fundingsubtype":"","investorislead":0,"amountvisibility":"Public","isextensionround":null,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$di6whFrza8jq1EjerFjFw3CTYo7T8wi04nY6zfpko5N5dIQ7JbtC1I","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"isjointventuregrant":0,"fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Non-Equity Funding","isgrant":true,"isicoevent":false,"amountnumber":4300000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCendTFCww","date":"Apr 2020","amount":"$16M","source":"https://techcrunch.com/2020/04/21/migvax-raises-12m-for-its-covid-19-vaccine-efforts/","eventtype":"FundingRoundEvent","investment":[{"name":"OurCrowd","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/ourcrowd","logokey":"$7IbHrXXd8dSbWrifZtvAYNCvwQvEjxCgGJeOg7DXKENs3TbpV3W9g1","tagline":null,"urlname":"/investor_page/ourcrowd","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgP7H-oQKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"GiKR2MD22LVoDDCPaniSN6r9E5JXTwGRW7RzdY6KIgEFZniAcnZZV4","fundingsubtype":"VC and Private Equity","investorislead":1,"amountvisibility":null,"isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":null,"leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$7IbHrXXd8dSbWrifZtvAYNCvwQvEjxCgGJeOg7DXKENs3TbpV3W9g1","leadcaption":"Lead ","followupcaption":""},{"name":"Happiness Capital","type":"Investor","amount":null,"hidden":false,"country":"Hong Kong","fullurl":"/investor_page/happiness-capital","logokey":"$mMwKPhP09i59M1mi6aPfH4FNW0U64X4AWYiRiLUkVEX8VHqgXaEs3r","tagline":null,"urlname":"/investor_page/happiness-capital","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4KuUi_IKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"EblXcXcAP3Nc3SJrtUSIvz5nvbpifaJxLTqFZZWeAsf1KpjKelzEW4","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":null,"isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":null,"leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$mMwKPhP09i59M1mi6aPfH4FNW0U64X4AWYiRiLUkVEX8VHqgXaEs3r","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"A Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":16000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"investmentstage":[],"exits":[],"investments":[],"portfolio":[],"funds":[],"founded":"3/2020","databases":[],"sharedspaces":[],"utilities":[],"contributors":[],"employeesworldwide":"","fundingtype":"Startup","parsedName":"MigVax","logourl":"https://storage.googleapis.com/clean-finder-353810/$tmjQ7WJeCcpkiRfvlGTxQrN1jQgf3YxL43lAyGBo4HbOfYGzkHvBXV","oglogourl":"https://storage.googleapis.com/clean-finder-353810/$tmjQ7WJeCcpkiRfvlGTxQrN1jQgf3YxL43lAyGBo4HbOfYGzkHvBXV","seoabout":"MigVax was established as a special purpose vehicle by Migal, which granted MigVax an exclusive, worldwide license to make, use, and practice the vaccine t...","seoTitle":"Israeli Startup","solutions":[],"teamMembersNumber":4,"primarySector":"Health Tech & Life Sciences","primary-sector-display":"block","classifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drugs Discovery & Development","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","classificationName":"sectorclassification"},{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Biologicals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","classificationName":"coretechnology"},{"depth":2,"name":"Molecules","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Jvz7ewLDA","classificationName":"coretechnology"},{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"}],"classificationDelimited":["SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA>Molecules#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Jvz7ewLDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA>Drugs Discovery & Development#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA>Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA"],"classificationsViewModel":"|0:>SectorClassificationModel|1:>SectorClassificationModel/Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA|2:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA/Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA|3:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA/Drugs Discovery & Development#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA|0:>IndustryClassificationModel|1:>IndustryClassificationModel/Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA/Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA|0:>TechnologyClassificationModel|1:>TechnologyClassificationModel/Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA|2:>TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA/Molecules#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Jvz7ewLDA|","classificationTrees":{"sector":[{"title":"Health Tech & Life Sciences","key":"0-0","path":"SectorClassificationModel>Health Tech & Life Sciences","children":[{"title":"Pharma & Medical Biotechnology","key":"0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology","children":[{"title":"Drugs Discovery & Development","key":"0-0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology>Drugs Discovery & Development"}]}]}],"targetCustomer":[{"title":"Healthcare & Life Sciences","key":"0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences","children":[{"title":"Life Sciences","key":"0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences","children":[{"title":"Pharmaceuticals","key":"0-0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences>Pharmaceuticals"}]}]}],"coreTechnology":[{"title":"Biologicals","key":"0-0","path":"TechnologyClassificationModel>Biologicals","children":[{"title":"Molecules","key":"0-0-0","path":"TechnologyClassificationModel>Biologicals>Molecules"}]}]},"sectorClassifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drugs Discovery & Development","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","classificationName":"sectorclassification"}],"coreTechnologyClassifications":[{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Biologicals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","classificationName":"coretechnology"},{"depth":2,"name":"Molecules","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Jvz7ewLDA","classificationName":"coretechnology"}],"targetCustomerClassifications":[{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"}],"classificationNames":{"sector":["Health Tech & Life Sciences","Pharma & Medical Biotechnology","Drugs Discovery & Development"],"coreTechnology":["Biologicals","Molecules"],"targetCustomer":["Healthcare & Life Sciences","Life Sciences","Pharmaceuticals"]},"section":null,"sectionParams":"","queryParams":"","popup_claim_profile":"false","claimedBadge":"none","display":{"mainContact":"none","climateTag":"none","seeMoreSimilarCompanisDisplay":"none","similarCompaniesTitleFontSize":"3.2rem","similarCompaniesTitle":"Similar Companies","similar_companies":[]},"mainContact":{},"_eventview":{"publicoffering_exit":[],"privateequityfunding":[{"id":"fkYqgLc12uNEN9fVHcklK4PCNaCTRtzZFUJDRLYRpjXV9ahZEghT03","date":"Aug 2022","amount":"$500K","source":"2022 Survey","eventtype":"FundingRoundEvent","investment":[{"name":"OurCrowd","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/ourcrowd","logokey":"$7IbHrXXd8dSbWrifZtvAYNCvwQvEjxCgGJeOg7DXKENs3TbpV3W9g1","tagline":null,"urlname":"/investor_page/ourcrowd","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgP7H-oQKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"BmNica7hiFMhm4mgszDUKrLAMU5vAj1ZYSz9h38QuE4EjeJGOER1QE","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$7IbHrXXd8dSbWrifZtvAYNCvwQvEjxCgGJeOg7DXKENs3TbpV3W9g1","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":"Follow on "}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Convertible Debt","style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Private Equity Funding","amountnumber":500000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"EZFf0ahwz2jaIyKZJsUsD34tw1b5RIfnFysRKGSP0rTr1DLylYmhEW","date":"Dec 2021","amount":"$500K","source":"2022 Survey","eventtype":"FundingRoundEvent","investment":[],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Convertible Debt","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":500000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCendTFCww","date":"Apr 2020","amount":"$16M","source":"https://techcrunch.com/2020/04/21/migvax-raises-12m-for-its-covid-19-vaccine-efforts/","eventtype":"FundingRoundEvent","investment":[{"name":"OurCrowd","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/ourcrowd","logokey":"$7IbHrXXd8dSbWrifZtvAYNCvwQvEjxCgGJeOg7DXKENs3TbpV3W9g1","tagline":null,"urlname":"/investor_page/ourcrowd","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgP7H-oQKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"GiKR2MD22LVoDDCPaniSN6r9E5JXTwGRW7RzdY6KIgEFZniAcnZZV4","fundingsubtype":"VC and Private Equity","investorislead":1,"amountvisibility":null,"isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":null,"leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$7IbHrXXd8dSbWrifZtvAYNCvwQvEjxCgGJeOg7DXKENs3TbpV3W9g1","leadcaption":"Lead ","followupcaption":""},{"name":"Happiness Capital","type":"Investor","amount":null,"hidden":false,"country":"Hong Kong","fullurl":"/investor_page/happiness-capital","logokey":"$mMwKPhP09i59M1mi6aPfH4FNW0U64X4AWYiRiLUkVEX8VHqgXaEs3r","tagline":null,"urlname":"/investor_page/happiness-capital","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4KuUi_IKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"EblXcXcAP3Nc3SJrtUSIvz5nvbpifaJxLTqFZZWeAsf1KpjKelzEW4","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":null,"isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":null,"leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$mMwKPhP09i59M1mi6aPfH4FNW0U64X4AWYiRiLUkVEX8VHqgXaEs3r","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"A Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":16000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"nonequityfunding":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgJCIvNm1Cww","date":"Nov 2021","amount":"$4.3M","source":"https://www.jpost.com/health-and-wellness/coronavirus/israels-migvax-oral-vaccine-scores-34-m-to-fast-track-development-684020","eventtype":"GrantEvent","granttype":0,"investment":[{"name":"The Coalition of Epidemic Preparedness Innovations (CEPI)","type":"Other","amount":0,"hidden":false,"country":"Norway","fullurl":"/company_page/the-coalition-of-epidemic-preparedness-innovations-cepi","logokey":"$di6whFrza8jq1EjerFjFw3CTYo7T8wi04nY6zfpko5N5dIQ7JbtC1I","tagline":"Innovation Partnership for Developing Vaccines to Stop Future Epidemics","urlname":"/company_page/the-coalition-of-epidemic-preparedness-innovations-cepi","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgJCo7YapCQw","fundingtype":"Other","leadpartner":null,"investmentid":"8951ee70-0616-4310-8a03-9e9414a4e07c","fundingsubtype":"","investorislead":0,"amountvisibility":"Public","isextensionround":null,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$di6whFrza8jq1EjerFjFw3CTYo7T8wi04nY6zfpko5N5dIQ7JbtC1I","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"isjointventuregrant":0,"fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Non-Equity Funding","isgrant":true,"isicoevent":false,"amountnumber":4300000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"merger_acquisitions":[],"others":[]}}